JPH0466205B2 - - Google Patents
Info
- Publication number
- JPH0466205B2 JPH0466205B2 JP22858083A JP22858083A JPH0466205B2 JP H0466205 B2 JPH0466205 B2 JP H0466205B2 JP 22858083 A JP22858083 A JP 22858083A JP 22858083 A JP22858083 A JP 22858083A JP H0466205 B2 JPH0466205 B2 JP H0466205B2
- Authority
- JP
- Japan
- Prior art keywords
- gelatin
- soft gelatin
- capsule
- drug
- gelatin capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000007903 gelatin capsule Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 7
- 210000000214 mouth Anatomy 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】
本発明は、口腔及び咽頭腔内で又は歯肉に局所
的に作用して効力を発揮させようとする薬剤を用
いて予防処置又は応急治療を行なうための施薬形
態に関するものである。このような局所的な処置
は、薬剤を刷毛で塗るか吹き付けるか薬剤で喇さ
せるか又は錠剤等をなめさせることにより行なわ
れる。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a form of administration for preventive treatment or emergency treatment using a drug that acts locally in the oral cavity and pharyngeal cavity or on the gums to exert its effect. It is. Such local treatment is carried out by brushing or spraying the drug, soaking it with a drug, or sucking a tablet or the like.
このような処置の治療効果は、薬剤に与えられ
ている形態がどの程度まで作用物質を作用部位に
集中させておくことを可能にするかにかかつてい
る。刷毛で塗られた薬剤と溶液は短時間の内に唾
液で薄められ、作用部位から遠ざけられてしま
う。又、喇溶液も唾液によつて薄められ、患者に
喇溶液を長時間口腔内に含ませておくことは困難
である。これに対して錠剤等は口腔内で崩壊する
のに時間がかり、薬剤をゆつくりとしか放出しな
いが、この場合には唾液によつて作用部位に運ば
れた薬剤量しか有効ではないという欠点を有して
いる。 The therapeutic effectiveness of such treatments depends on the extent to which the form in which the drug is presented allows the active substance to remain concentrated at the site of action. Medications and solutions applied with a brush are diluted by saliva within a short time and moved away from the site of action. Furthermore, the saliva solution is diluted by saliva, making it difficult for the patient to keep the solution in the oral cavity for a long period of time. On the other hand, tablets and the like take time to disintegrate in the oral cavity and release the drug only slowly, but in this case they have the disadvantage that only the amount of drug carried to the site of action by saliva is effective. have.
本発明の課題は前述の欠点を排除し、作用部位
に於ける接触時間ができるだけ長く、液状の薬剤
にも固体状の薬剤にも適し、作用物質をできるだ
け均一に、しかも刺激なしに放出し、生理学的に
中立の補助物質、特に糖又は刺激物質のようなカ
リエス促進作用を持たない補助物質しか用いられ
ていない薬剤形態を提供することである。 The object of the present invention is to eliminate the above-mentioned disadvantages, to achieve as long a contact time at the site of action as possible, to be suitable for both liquid and solid drugs, to release the active substance as uniformly as possible and without irritation; It is an object of the present invention to provide a drug form in which only physiologically neutral auxiliary substances are used, in particular auxiliary substances that do not have a caries-promoting effect, such as sugars or stimulants.
本発明の目的は簡単な薬剤形態を与えて、作用
物質と補助物質とから成る混合物ができるだけ長
い接触時間に亙つて粘膜に対して高い付着性を有
するようにすることである。 The aim of the invention is to provide a simple drug form in which the mixture of active substance and auxiliary substance has a high adhesion to the mucous membranes for as long a contact time as possible.
本発明の課題は、ゼラチンゲルに作用物質を分
散状態又は溶解状態で含有させ、このゼラチンゲ
ルを公知の形式で軟質ゼラチンカプセルに加工す
ることによつて解決された。このようにして製造
された軟質ゼラチンカプセルはなめられるか又は
かまれる。 The object of the invention was achieved by containing the active substance in dispersed or dissolved form in a gelatin gel and processing this gelatin gel in a known manner into soft gelatin capsules. The soft gelatin capsules thus produced are sucked or chewed.
軟質ゼラチンカプセルの製造法は以前から公知
であり、例えばChemie出版社発行のK・Voigt
著の「Lehrbuch der phamazeutischen
Technologie」(薬剤工学教本)の第232頁〜235
頁に記載されている。この場合には従来の製造技
術とは異つてゼラチンバンドはカプセルの壁厚さ
を大きくするためにできるだけ厚く注型される。 Methods for producing soft gelatin capsules have been known for some time, for example in K. Voigt, published by Chemie Publishing House.
"Lehrbuch der phamazeutischen" written by
Pages 232-235 of "Technology" (Pharmaceutical Engineering Textbook)
It is written on the page. In contrast to conventional production techniques, in this case the gelatin band is cast as thick as possible in order to increase the wall thickness of the capsule.
しかもカプセルは成形品にある程度のフレキシ
ブル性を与えるために気体コアを有しているの
で、歯あたりが良くなり、しかも歯が軽くあたつ
ただけではカプセルが壊れ難くなり、口腔内に於
ける作用物質の有効時間が長くなる。使用される
ゼラチン材料は通常は一般的な軟ゼラチンカプセ
ルの組成と似た組成を有している。それにも拘ら
ずゼラチンカプセルの質的な組成の選択は重要な
意味を持つている。何故ならばゼラチンカプセル
はなめるか又はかんだときに素早く軟化するが、
ゆつくりとしか崩壊しないものでなければならな
いからである。このようにゼラチン材料を選ぶと
ゼラチンの付着性によつてゼラチン材料は口腔内
に分配されかつ口内粘膜に付着するが口内粘膜と
できるだけ長く接触させられた状態に留められる
ようになる。 In addition, the capsule has a gas core to give the molded product a certain degree of flexibility, so it feels better against the teeth, and the capsule is less likely to break even when the teeth touch it lightly, making it more effective in the oral cavity. The effective time of the substance increases. The gelatin material used usually has a composition similar to that of common soft gelatin capsules. Nevertheless, the selection of the qualitative composition of the gelatin capsule has important implications. This is because gelatin capsules quickly soften when licked or chewed.
This is because it must be something that will only collapse slowly. When a gelatin material is selected in this manner, the adhesive properties of gelatin allow it to be distributed within the oral cavity and adhere to the oral mucosa, but remain in contact with the oral mucosa for as long as possible.
驚くべきことには前述の効果は軟質ゼラチンカ
プセルのために通常使用されているゼラチンカプ
セルの公知の組成で達成することができることが
確認された。 It has surprisingly been found that the aforementioned effects can be achieved with known compositions of gelatin capsules, which are commonly used for soft gelatin capsules.
本発明のもう一つの利点はゼラチン材料内に一
連の作用物質、例えばエーテル油又は収斂性のチ
ンキを溶解させることができるので、作用物質が
分子の状態で分散して作用するようになるという
ことである。 Another advantage of the invention is that a range of active substances, such as ethereal oils or astringent tinctures, can be dissolved within the gelatin material, so that the active substances become dispersed in molecular form and act. It is.
次に本発明の1実施例を説明するが、この実施
例は本発明をこれに限定するものではない。 Next, one embodiment of the present invention will be described, but this embodiment does not limit the present invention.
組成が46.00%のゼラチンと17,23%のグリセ
リンと36.77%の水である、温度70℃である100.0
℃Kgのゼラチン溶融物にこれを撹拌しながら順
次、保存料の24.3%水溶液が1.07Kg、甘味料の
22.8%水溶液が5.04Kg、エーテル油混合物が0.65
Kg、収斂性のチンキの混合物が1.02Kg、着色料又
は混合着色料の62.5%分散水液が0.08Kgづつ添加
される。 100.0 whose composition is 46.00% gelatin, 17,23% glycerin and 36.77% water, temperature 70℃
While stirring, 1.07 kg of a 24.3% aqueous solution of preservative and 1.07 kg of sweetener were added to ℃ kg of melted gelatin.
5.04Kg of 22.8% aqueous solution, 0.65Kg of ether oil mixture
Kg, 1.02 Kg of astringent tincture mixture, and 0.08 Kg of 62.5% aqueous dispersion of colorant or mixed colorant are added.
本発明の軟質ゼラチンカプセルを製造するため
には、シーラ・ロータリ・ダイ・プロセスで重量
1032.0mgの成形体が打抜かれる。形状を安定させ
るためにはカプセル内に0.32mlの窒素が充填され
る。2〜3日の内のカプセルは660.0mgの最終重
量に乾燥される。 To produce the soft gelatin capsules of the present invention, a sheera rotary die process is used.
A 1032.0 mg compact is punched out. To stabilize the shape, 0.32 ml of nitrogen is filled into the capsule. The capsules are dried within 2-3 days to a final weight of 660.0 mg.
Claims (1)
ラチンカプセルであつて、軟質ゼラチンカプセル
が壁部に作用物質を分散状態又は溶解状態で含有
しており、コアには気体しか含有していないこと
を特徴とする軟質ゼラチンカプセル。 2 粘膜に対する高い付着性を得るためにゼラチ
ン材料が40%〜50%のゼラチンと20%〜30%のグ
リセリンと20%〜30%の水から成つている、特許
請求の範囲第1項記載の軟質ゼラチンカプセル。[Scope of Claims] 1. A soft gelatin capsule for use as a medicine for the oral cavity and pharyngeal cavity, the soft gelatin capsule containing the active substance in the wall in a dispersed or dissolved state, and the core containing only a gas. A soft gelatin capsule characterized by containing no gelatin. 2. The gelatin material according to claim 1, wherein the gelatin material consists of 40% to 50% gelatin, 20% to 30% glycerin and 20% to 30% water in order to obtain high adhesion to mucous membranes. Soft gelatin capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22858083A JPS60120811A (en) | 1983-12-05 | 1983-12-05 | Soft gelatin capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22858083A JPS60120811A (en) | 1983-12-05 | 1983-12-05 | Soft gelatin capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60120811A JPS60120811A (en) | 1985-06-28 |
| JPH0466205B2 true JPH0466205B2 (en) | 1992-10-22 |
Family
ID=16878586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22858083A Granted JPS60120811A (en) | 1983-12-05 | 1983-12-05 | Soft gelatin capsule |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60120811A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797221B (en) | 2002-12-13 | 2013-06-12 | 杜雷科特公司 | Oral drug delivery system comprising high viscosity liquid carrier materials |
| CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| AU2008335809A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| WO2014144975A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| CA3028450A1 (en) | 2016-07-06 | 2018-01-11 | Durect Corporation | Oral dosage form with drug composition, barrier layer and drug layer |
-
1983
- 1983-12-05 JP JP22858083A patent/JPS60120811A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60120811A (en) | 1985-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU707749B2 (en) | Medical Treatment | |
| CN1267079C (en) | Herbal composition for improving oral hygiene, and methods of using same | |
| US5977087A (en) | Topical preparation for treatment of aphthous ulcers and other lesions | |
| US6159955A (en) | Use of hyaluronic acid and a NSAID for the manufacture of a medicament for the treatment of mucosal diseases | |
| JPH02212417A (en) | Capsule of soft gelatine masticatory and eatable | |
| JP5897509B2 (en) | Recessed adhesive patch for use in the mouth | |
| JP2006525986A (en) | Confectionery products for delivering pharmaceutically active agents to the throat | |
| US5972906A (en) | Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof | |
| JPS61183220A (en) | Analgesic medicinal composition, manufacture and use | |
| US3257276A (en) | Oral analgesic preparation | |
| KR20150131302A (en) | Compositions for treatment of xerostomia and for tooth treatment | |
| JPS61275220A (en) | Novel pharmaceutical composition | |
| RU2060033C1 (en) | Agent for treatment and prophylaxis of parodontium disease and a method of its preparing | |
| DE69817379T2 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING IBUPROFEN AND DOMPERIDON FOR TREATING MIGRAINE | |
| JPH0466205B2 (en) | ||
| JPH08295637A (en) | Oral topical agent | |
| US2333950A (en) | Therapeutic pectous product | |
| EA006582B1 (en) | Pharmaceutical disinfective preparation based on usnic acid sodium salt and medical plants and methods for preparation thereof | |
| JPH0656677A (en) | Antacid composition | |
| RU2201194C2 (en) | Medicinal film "piyavit" for treatment of inflammatory diseases of parodontium | |
| US3914433A (en) | Method of relieving the discomfort of pharyngitis | |
| US5874065A (en) | Oral anti-acid paste and methods of use | |
| RU2197950C2 (en) | Agent for mouth cavity rinsing | |
| WO2015161180A1 (en) | Analgesic compositions and methods of use | |
| KR102375872B1 (en) | Pharmaceutical composition for preventing or treating periodontal disease which has improved convenience for internal use through size reduction for formulation using iLet(innovative Low excipient tablet) technology comprising titrated extract of the unsaponifiable fraction of Zea Mays L. and extract of Magnoliae Cortex |